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Abstract
Purpose: To reduce radiation doses to the tongue, a patient-specific semi-customized tongue displacement device
(SCTDD) was developed using a 3D printer (3DP) for head and neck (H&N) radiation therapy (RT). Dosimetric
characteristics of the SCTDD were compared with those of a standard mouthpiece (SMP).
Materials and methods: The SCTDD consists of three parts: a mouthpiece, connector with an immobilization
mask, and tongue displacer, which can displace the tongue to the contralateral side of the planning target volume.
Semi-customization was enabled by changing the thickness and length of the SCTDD. The instrument was printed
using a 3DP with a biocompatible material. With the SCTDD and SMP, two sets of planning computed tomography
(CT) and tomotherapy plans were obtained for seven H&N cancer patients. Dosimetric and geometric characteristics
were compared.
Results: Using the SCTDD, the tongue was effectively displaced from the planning target volume without
significant tongue volume change compared to the SMP. The median tongue dose was significantly reduced (29.6
Gy vs. 34.3 Gy). The volumes of the tongue receiving a dose of 15 Gy, 30 Gy, 35 Gy, 45 Gy, and 60 Gy were
significantly lower than using the SMP.
Conclusion: The SCTDD significantly decreased the radiation dose to the tongue compared to the SMP, which may
potentially reduce RT-related tongue toxicity.
Keywords: Tongue displacement, 3D printing, Head and neck cancer, Tomotherapy
Introduction
Radiation therapy (RT) has played an important role as a
standard treatment for head and neck squamous cell
carcinoma (HNSCC) [1–4] with surgery and chemother-
apy. However, it is not an easy task to meet the aim of
RT, which delivers a curable dose to a target volume
while minimizing the dose to organs at risk (OARs) near
the target volume because head and neck (H&N) tumors
usually overlap or are adjacent to normal organs. There
are many OARs of concern in the RT planning for H&N
cancer, such as the brain, brainstem, optic apparatus,
parotid gland, submandibular glands, pharyngeal mus-
cles, laryngeal structures, and oral cavity (OC), including
the tongue. Intensity modulated radiation therapy
(IMRT) technique has made a significant contribution to
reduce dose of these OARs [1, 2, 5–7], but reduction of
OC dose to a meaningful level still remain a big chal-
lenge because it is close to target volume and
immobilization is not an easy task in H&N RT.
The tongue is a subsite of the OC and is not separately
described in the OAR delineation guidelines [8]. How-
ever, it plays important roles in taste, saliva production,
speech, and swallowing [5, 7, 9, 10], so it is important to
minimize the radiation dose to the tongue for better
quality of life following RT. High mean dose of the
tongue is closely related to movement of tongue and
taste dysfunction that affect quality of speech and weight
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loss respectively in H&N RT [9, 10]. Percentage relative
taste loss was not observed until radiation doses of 20
Gy had been reached. Between 20 Gy and 40 Gy, taste
loss increased rapidly, while over 90% relative taste loss
was observed at the 60 Gy dose level [11, 12]. Shi. et al.
reported that significant impaired threshold of taste was
revealed at 30 Gy [12].
Some clinical strategies have been used to reduce the
tongue dose in H&N RT. First, radiation dose
optimization permits protection of the tongue by
employing advanced RT techniques, such as
intensity-modulated radiation therapy (IMRT) [6, 7].
However, when the tongue is adjacent to the target vol-
ume, H&N RT can be challenging. Second, Kil et al. re-
ported that the ‘stick-out’ position of the tongue without
an intraoral device (IOD) can be useful to reduce the
tongue dose, especially for tongue base dose reduction
[13]. However, it does not seem likely that good position
reproducibility will be provided during IMRT with ef-
fective tongue displacement to the contralateral side of
the target. Finally, as an active approach, a technique
that can intentionally displace the tongue from the tar-
get volume can be used by employing a tongue displace-
ment device (TDD) during RT [14].
Traditionally, a standard IOD (SIOD), such as a
mouthpiece, bite-block, or tongue blade, has been used
to reduce the dose and enhance immobilization of the
tongue by displacement and/or compression of the
tongue [14–19]. However, these have some limitations
for clinical implementation. First, a commercially avail-
able standard mouthpiece (SMP, Fig. 1d), which has been
the most commonly used SIOD, is not effective to dis-
place and/or immobilize the tongue during HNSCC RT
because it is designed for different purposes, such as an
endoscopy mouthpiece or a tooth protector. Displace-
ment of the tongue to the contralateral side of the plan-
ning target is very effective to reduce the dose to the
tongue in ipsilateral H&N irradiation for well-lateralized
H&N cancer, such as tonsil and OC cancer, but it is im-
possible to meet this goal with a commercially available
SIOD. Finally, an SIOD is not suitable for
patient-specific customization. Patients have different
OC structures, and jaw opening depends on tumor loca-
tion and size and surgery conditions. If the IOD does
not fit well with the OC structure and its purposes, it
does not provide patient comfort or dosimetric benefit.
Therefore, to solve these problems, a patient-specific
TDD is needed. Janson and Bodard reported that dosi-
metric benefits with patient comfort were obtained by
using patient-specific IODs supplied by dental services
for H&N RT [14, 16]. However, it is not an easy task for
clinical implementation because it requires a long
Fig. 1 a Top and b front views of the 3D model for the semi-customized tongue displacement device. It was printed using a 3D printer with a
biocompatible material (c). d Commercially available standard mouthpiece, which has been the most commonly used device in H&N RT
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waiting time with high cost. In addition, such dental ser-
vice is not available for all RT facilities.
In order to displace and immobilize the tongue in ipsi-
lateral H&N RT for well-lateralized HNSCC, we devel-
oped a unique TDD that can be semi-customized for
various patient conditions using 3D printing technology.
The manufacturing process of the semi-customized
TDD (SCTDD) was introduced, and dosimetric charac-
teristics were compared with those of an SMP.
Materials and methods
Development of a patient-specific semi-customized
tongue displacement device
We designed a unique SCTDD combining the merits ob-
tained from the many papers mentioned in the introduc-
tion and our clinical experience. The major concerns of
the SCTDD design were displacement and sticking out,
simple position verification, and robust immobilization of
the tongue with patient-specific semi-customization for
patient comfort. For these, the SCTDD consists of three
parts: a mouthpiece, connector, and tongue displacer (Fig.
1). The mouthpiece has tooth stoppers on the upper and
lower sides of the mouthpiece, an airway, and a position
guide bar with a position verification window for the
tongue. A tooth stopper, which is the contact point of the
patient’s teeth, was designed to improve reproducibility of
the biting position and prevent teeth from slipping. When
the patient bites the tooth stopper using central incisors
and then sticks out the tongue until the tip reaches the
guide bar, the tongue moves along the guide groove of the
displacer (red dotted arrows in Fig. 1). As a result of this,
the tongue is naturally displaced to the contralateral side
of the target. In order to improve the interfractional repro-
ducibility of the tongue position, a verification window
was designed to verify the position of the tip of the tongue
during patient setup. To ensure natural breathing of the
patient during treatment, we added an airway on the front
of the mouthpiece, starting from the opposite side of the
SCTDD displacer. Finally, we designed two connectors
that can be attached to the immobilization mask on the
front panel of the mouthpiece.
For patient-specific semi-customization of the TDD,
different sizes of the SCTDD were designed by combin-
ing different thicknesses from 5mm to 20 mm in 5mm
increments and lengths from 40mm to 70mm in 10
mm increments to cover different jaw openings and
lengths of the OC (Fig. 1c), respectively. For simplifica-
tion of the manufacturing process, the SCTDD was de-
signed using a computer-aided design (CAD) program
and converted into a stereolithography file format, which
can be identified by a three-dimensional printer (3DP).
The designed SCTDD was printed using a fused depos-
ition modeling 3DP (3DISON Multi, Rokit, Korea) with
a biocompatible 3DP material (Kitchen & Deco, Rokit,
Korea).
We measured the average 3D printing times, excluding
the modeling, to evaluate the efficiency of the SCTDD
manufacturing procedure for clinical implementation.
Patient selection and simulation
This dosimetric study did not involve any human or ani-
mal experiments. With approval from the institutional
review board, between June 2016 and October 2016,
seven consecutive patients, three for tonsil cancer and
four for OC cancer with histologically proven HNSCC,
who underwent ipsilateral H&N RT with helical
tomotherapy (TomoHD™, Accuray, USA) were included
in this study (Table 1). All methods were performed in
accordance with the institutional review board for retro-
spective study. All of this process have been performed
on the informed consent. All patients were immobilized
by an individually customized thermoplastic mask
(Aquaplast RT™, Q-fix, USA) with SCTDD and SMP in
the supine position.
An SCTDD was fitted to the patient by an internal
guideline as described in the following procedures. Be-
fore the planning computed tomography (CT), a
SCTDD was selected based on the physical length of the
jaw opening (upper to lower incisor) and depth of the
OC in the diagnostic CT, which correspond to the thick-
ness and length of the SCTDD, respectively.
For correct use and elimination of the sense of rejec-
tion by the SCTDD, the patient was trained using their
own SCTDD for 10 min according to the design pur-
poses described in the previous session. After the patient
was familiarized with the SCTDD, the tongue was stuck
out as much as possible until the tip reached the tongue
position guide bar. After confirming this through the
tongue position verification window, the patient was
immobilized using a thermoplastic mask in conjunction
with the connector of the SCTDD to improve the inter-
fractional reproducibility.
For the SMP, most procedures were the same as for
the SCTDD, but a single sized standard model was used.
In addition, the SMP was designed to depress the tongue
Table 1 Patients’ characteristics
Case Gender Age Primary Site Clinical Stage Histology Aim of RT
1 Male 40 Tonsil cT2N2bM0 Squamous Definitive
2 Female 46 Oral cavity pT4aN0M0 Squamous Adjuvant
3 Male 56 Tonsil cT1N2aM0 Squamous Definitive
4 Male 64 Tonsil cT2N1M0 Squamous Definitive
5 Male 54 Oral cavity pT4aN2bM0 Squamous Adjuvant
6 Female 60 Oral cavity pT2N1M0 Squamous Adjuvant
7 Male 72 Oral cavity pT2N1M0 Squamous Adjuvant
Abbreviation: RT radiation therapy
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and immobilize it without position verification (Fig. 1d).
Two sets of planning CT images were obtained under
the same scan conditions with an SCTDD and an SMP
for each patient and were transferred into TPS (Pinna-
cle3®, version 9.2; Philips Medical System, USA) for
contouring.
Treatment planning
For tonsil cancer patient-aimed definitive RT, the gross
tumor volume (GTV) and clinical target volume (CTV)
were delineated on both CT image sets, while only CTV
was delineated for OC cancer patient-aimed adjuvant
RT. The planning target volumes (PTV, P_GTV and
P_CTV) were generated with an isotropic expansion of
3 mm from GTV and CTV, respectively, which were
modified so that the expanded PTVs did not exceed the
actual anatomic boundaries, such as the spinal cord and
skin surface. OAR, including the spinal cord, brainstem,
parotid gland, and tongue, were delineated on both CT
image sets according to internal guidelines based on a
reference [8]. The planning volume for the spinal cord
(P-cord) was generated by adding a 3-mm margin to the
actual spinal cord. All contours were delineated by a ra-
diation oncologist based on the same rules for
consistency.
For dose planning, all contour data with the planning
CT was transferred to TPS for tomotherapy (Tomother-
apy, Accuray, USA). For dosimetric comparison, helical
tomotherapy plans were generated for both the SCTDD
and SMP with a 6 MV photon beam. The same dose
constraints and prescriptions were used in both plans
based on internal guidelines as follows: total doses of 66
Gy and 60 Gy were prescribed to P_GTV and P_CTV,
respectively, in 33 fractions using the simultaneously in-
tegrated boost technique for tonsil cancer, while a total
dose of 59.4 Gy was prescribed to P_CTV in 27 fractions
for OC cancer.
Two constraints were set at the highest priority level:
95% of PTVs should receive at least 100% of the pre-
scription dose, and the maximum dose to P-cord should
not exceed 45 Gy (Dmax < 45 Gy). In order to achieve the
most homogenous dose distribution as possible within
and around the PTV, 99% of the PTV volume should re-
ceive at least 95% of the prescription dose, and the vol-
ume receiving ≥110% of the prescribed dose should not
be greater than 1 cm3 in total volume. The constraints at
the second priority level were to limit the mean dose
(Dmean) under 26 Gy and 30 Gy for the parotid and
tongue, respectively. The lowest level constraint was to
limit the dose to the brainstem: Dmax should not exceed
54 Gy.
For each plan, the same number of iterations was used
during the dose optimization process. During inverse
planning, once PTV constraints were reached, the
optimization was continued to reduce the doses to OAR
until the iteration limit was reached while maintaining
the PTV dose. In both plans, a field width of 2.5 cm,
modulation factor of 2.0, and pitch of 0.287 were used
to avoid the thread effect [20]. Dose calculation was con-
ducted using the collapsed-cone convolution algorithm
[21, 22].
Evaluation of the geometric and dosimetric effects of the
SCTDD
We evaluated the geometric and dosimetric effects of
the SCTDD compared with those of the SMP. For com-
parative evaluation of the geometrical change on the
tongue, tongue volume and percent of tongue volume
outside the PTV were measured in both the SCTDD
and SMP plans.
In order to evaluate the effect of the SCTDD on plan
quality, the minimum dose received by 95% (D95), 50%
(D50), and 2% (D2) of the PTVs in the SCTDD plan were
compared with those of the SMP plan data. The homo-
geneity index (HI = (D2-D98)/D50) was also compared. In
addition, several relevant dosimetric parameters on these
OAR were used for comparison: Dmean of the parotid;
Dmax of the P-cord and brainstem; and the percentages
of tongue volume that received a dose of 15 Gy (V15),
30 Gy (V30), 35 Gy (V35), 45 Gy (V45), 60 Gy (V60), or
more; and Dmax and Dmean of the tongue.
Statistical analysis of the dosimetric comparison be-
tween the SMP and SCTDD was done using a Wilcoxon
signed-rank test. A probability level with a p-value <
0.05 was considered significant.
Results
Geometrical effect of the semi-customized tongue
displacement device
We designed (Fig. 1a and b) and printed (Fig. 1c) 16
SCTDD models with different depths and lengths to
cover various patient conditions. 3D printing of the
SCTDD took a minimum of 60 min and a maximum of
120 min depending on the SCTDD size. Additionally,
approximately 30 min of post processing were required.
The average thickness and length of the SCTDD for
seven patients were 2.1 cm and 6.8 cm, respectively. The
connector of the SCTDD (Fig. 2b) provided better fix-
ation with a thermoplastic mask compared with the
SMP (Fig. 2a). Using an SMP, depression and
immobilization of the tongue were possible in all pa-
tients, but displacement of the tongue from PTV (plan-
ning target volume) was not effective (Fig. 2c). In
contrast, using an SCTDD, the tongue was effectively
displaced from PTV and immobilized in all patients (Fig.
2d). These effects were well represented in the statistical
analysis related to tongue volume as follows. The me-
dian tongue volumes were similar between the SMP and
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the SCTDD (82.6 cm3 vs. 80.5 cm3, p = 0.578). However,
a significant increase in median percentage of tongue
volume outside the PTV was observed in the SCTDD
compared with the SMP (91.3% vs. 86.4%, p = 0.016)
(Table 2).
Dosimetric comparison between the SMP and SCTDD
By comparing the SCTDD with the SMP, the dosimetric
characteristics for the PTVs, parotid grands, P-cord, and
brainstem were calculated, as summarized in Table 3.
For target dose coverage, no significant dose differences
between the SCTDD and SMP were observed in D98,
D50, and D2 for all PTVs (p > 0.05). In addition, no sig-
nificant dose difference was observed in median of
Dmean for the parotid (15.5 Gy vs. 15.3 Gy, p = 0.578) or
median of Dmax for P-cord (27.1 Gy vs. 26.6 Gy, p =
0.938) and the brainstem (21.3 Gy vs. 19.2 Gy, p = 0.469).
In connection with geometrical change of the tongue
by using an SCTDD, the tongue was effectively displaced
from the high dose region near PTV (Fig. 2d), while a
partial volume of the tongue received a high dose similar
to the prescribed dose in the SMP (Fig. 2c). The median
of Dmean for the tongue was significantly reduced by
15.9% in the SCTDD (29.6 Gy, IQR: 27.3, 30.4) com-
pared with the SMP (34.3 Gy, IQR: 33.0, 35.5) (p = 0.016)
(Table 2). Moreover, median of V15, V30, V35, V45, and
V60 for the tongue were significantly lower in the
SCTDD (79.9, 37.8, 30.6, 22.7, and 7.4%, respectively)
than the SMP (89.7, 48.3, 41.4, 29.4, and 13.7%, respect-
ively) (all p < 0.05). However, no significant difference in
median of Dmax for the tongue was observed between
the SCTDD (62.3, IQR: 62.1, 69.0 Gy) and the SMP
(62.9, IQR: 62.3, 69.3) (p = 0.078).
Discussion
The tongue plays a very important role in taste, speech,
and swallowing functions. Reducing the radiation dose
to the tongue can retain these functions following RT.
Several authors have shown evidence of this. Sapir et al.
reported significant association between dysgeusia and
radiation dose to the tongue [9]. Jacobi et al. showed
that changes in speech are related to mean doses to the
Fig. 2 Patient setup photograph with a a standard mouthpiece (SMP) and b semi-customized tongue displacement device (SCTDD) for a patient
who underwent H&N tomotherapy. Isodose distributions of this patient in the axial section for the c SMP and d SCTDD plans are also shown. The
tongue was effectively displaced from the high-dose region near the planning target volume (yellow arrows) by using the SCTDD, while a partial
volume of the tongue received a high dose equivalent to the prescribed dose (red arrow) in the SMP plan because SMP only depressed tongue
(yellow arrow) without displacing it to the contralateral side of the target
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tongue [10]. Schwartz et al. suggested that V30 < 65%
and V35 < 35% for the anterior OC are predictive factors
for swallowing dysfunctions [23]. Eisbruch et al. showed
that the mean dose to the OC, representing the RT ef-
fect on the minor salivary glands, is a significant factor
of dry mouth [5]. In the current study, the use of the
SCTDD decreased the mean dose to the tongue through
V15 to V60 compared to the SMP without sacrifice of
plan quality or patient setup stability.
IOD has been playing an important role in reducing
the dose of oral cavity and its subsites, as well as im-
proving setup uncertainty [24, 25]. For effective working
of the IOD, it should cover various patient conditions
such as different jaw opening and complex oral cavity
structure based on surgery result. So, we developed
unique SCTDD manufacturing process that can be real-
ized in clinic based on semi-customization using a CAD
software and 3D printing technology. For
semi-customization, we first designed an ideal model of
the SCTDD, and then created many different size
SCTDD models to fit various patient conditions using
copy, resizing, and modification tool provided by com-
mercial CAD software. Furthermore 3D printing tech-
nology made it possible to manufacture these models in
short time with low cost by clinical staff, that were not
possible in conventional manufacturing process such as
milling or casting process. Our proposal is useful to han-
dle unexpected patient condition because SCTDD model
can be modified and printed within half day if prepared
SCTDD does not fit the patient condition.
Table 3 Comparisons of dosimetric characteristics
Parameters SMP SCTDD p-value
Tonsil Cancer P_GTV D2% (Gy) 68.5 (68.3, 68.6) 68.3 (68.0, 68.4) 0.205
D98% (Gy) 65.7 (65.6, 65.7) 65.7 (65.6, 65.7) 0.750
D50% (Gy) 67.3 (67.2, 67.3) 67.1 (67.1, 67.2) 0.250
HI 0.042 (0.039, 0.043) 0.039 (0.034, 0.042) 0.250
P_CTV D2% (Gy) 68.1 (68.0, 68.1) 67.9 (67.7, 67.9) 0.250
D98% (Gy) 59.5 (58.8, 59.8) 58.5 (58.4, 59.2) 0.250
D50% (Gy) 63.5 (63.3, 63.8) 63.0 (62.5, 63.6) 0.250
HI 0.136 (0.131, 0.144) 0.149 (0.136, 0.152) 0.250
Oral Cavity cancer P_CTV D2% (Gy) 62.2 (61.8, 62.3) 62.0 (61.7, 62.2) 0.125
D98% (Gy) 58.7 (58.6, 58.8) 58.7 (58.7, 58.8) 0.875
D50% (Gy) 60.9 (60.6, 61.0) 60.8 (60.6, 61.0) 0.375
HI 0.058 (0.050, 0.060) 0.054 (0.048, 0.058) 0.625
Parotid glands Dmean (Gy) 15.3 (13.4, 15.7) 15.5 (13.1, 16.9) 0.578
P-cord Dmax (Gy) 26.6 (24.7, 30.7) 27.1 (23.4, 30.5) 0.938
Brainstem Dmax (Gy) 19.1 (15.0, 22.3) 21.3 (15.5, 23.4) 0.469
Values are presented as median (IQR Q1, Q3)
Table 2 Comparison of geometric and dosimetric characteristics for tongue: SMP versus SCTDD
Parameters SMP SCTDD p-value
Tongue volume 82.6 cm3 (73.1, 95.4) 80.5 cm3 (77.7, 100.5) 0.578
Percent of tongue volume outside the PTV 86.4% (84.9, 90.8) 91.3% (87.3, 91.9) 0.016a
V15 89.7% (83.3, 94.3) 79.9% (71.7, 81.9) 0.016
a
V30 48.3% (46.1, 53.3) 37.8% (34.1, 40.9) 0.016
a
V35 41.4% (37.9, 47.1) 30.6% (27.2, 34.5) 0.016
a
V45 29.4% (27.4, 36.6) 22.7% (17.2, 24.2) 0.016
a
V60 13.7% (8.0, 16.1) 7.4% (6.6, 12.6) 0.016
a
Dmean 34.3 Gy (33.0, 35.5) 29.6 Gy (27.3, 30.4) 0.016
a
Dmax 62.9 Gy (62.3, 69.3) 62.3 Gy (62.1, 69.0) 0.078
Abbreviations: IQR interquartile range, SMP standard Mouthpiece, SCTDD semi-customized tongue displacement device, VD (15, 30, 35, 45, and 60) the percentage of the
tongue volume that received D (15, 30, 35, 45, and 60) Gy or more, Dmean mean dose, Dmax maximum dose.
aStatistically significant
Values are presented as median (IQR Q1, Q3)
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There are some considerations for clinical implemen-
tation of the SCTDD. For accurate customization of the
TDD, the most important factor is to select the proper
thickness and length of the SCTDD for a patient. Until
now, we applied an SCTDD to 17 patients; seven in this
study and 10 not included to whom only SCTDD were
applied so that comparison with SMP could not be per-
formed. In these 17 patents, 12 of 13 patients for defini-
tive setting had SCTDDs with thicknesses of 2~2.5 cm
and lengths of 6.5~ 7 cm, while one patient had an
SCTDD with a thickness of 1.5 cm and length of 6.5 cm.
Of four patients for post-op setting, three had an
SCTDD with a thickness of 1 cm and a length of 6.5 cm,
while one had an SCTDD with a thickness of 1.5 cm and
a length of 7 cm. In patients for post-op setting, it was
not possible to apply an SMP because they had difficulty
opening the jaw sufficiently, while an SCTDD was very
easy to apply. In this context, we can categorize the
SCTDD size into two groups: one with a thickness of
2.25 cm and a length of 6.75 cm, which is very close to
results of seven present patients, for definitive RT pa-
tients and one with a thickness of 1.25 cm and a length
of 6.75 cm for post-op patients.
The SCTDD is placed with a patient’s mouth open. As the
course of RT progresses, oral discomfort or pain may in-
crease because of oral mucositis and trismus caused by RT.
For this reason, the SCTDD should have a rounded edge de-
sign with a smooth surface. Additionally, biocompatible and
soft material is recommended for 3D printing, with smooth
surface treatment as a post processing step. Fortunately,
various types of 3D printing material that meet these re-
quirements are commercially available, and this will be
broaden by rapid advancement of 3D printing technology.
Position reproducibility of the tongue with the SCTDD
is also very important, although it is not included in this
study. To obtain robust positional reproducibility, we in-
troduced two key points into the design of the SCTDD:
the connector, which connects to a thermoplastic mask,
and a tongue position guide bar with a verification win-
dow. Both of these features were very effective at main-
taining positional reproducibility of the SCTDD and the
tongue, as well as reduction of patient setup time. Evalu-
ation of the long-term positional reproducibility can be
contributed to improve the SCTDD design based on the
setup image.
Conclusions
By employing 3D printing technology with an in-house
manufacturing process, a unique SCTDD was developed
to displace and immobilize the tongue for ipsilateral
H&N RT. It significantly decreased the radiation dose to
the tongue compared to an SMP and could potentially
reduce RT-related tongue toxicity. Furthermore, with
rapid advancement of 3D printing technology, this
investigation may also contribute to improve manufac-
turing processes for patient-specific customized devices
for RT.
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